Literature DB >> 17435284

Oral administration activity determination of recombinant osteoprotegerin from silkworm larvae.

Hai-Long Xiao1, Yao-Zhou Zhang, Xiang-Fu Wu.   

Abstract

Osteoprotegerin (OPG) regulates the formation of osteoclasts and is involved in the regulation of bone resorption and remodeling. To investigate the feasibility of using silkworm (Bombyx mori) larvae to produce recombinant osteoprotegerin as a oral administration drug, the rh-OPG was expressed in the larvae of silkworm through the silkworm baculovirus expression system, and was orally administered to mice. Compared with the control, oral administration of rh-OPG was effective to decrease serum calcium concentration in normal mice, and block the bone loss induced by the loss of estrogen in ovariectomized mice. These results indicated that oral administration of rh-OPG expressed in silkworm larvae had the proper bioactivity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17435284     DOI: 10.1007/bf02686103

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  14 in total

1.  Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.

Authors:  E Tsuda; M Goto; S Mochizuki; K Yano; F Kobayashi; T Morinaga; K Higashio
Journal:  Biochem Biophys Res Commun       Date:  1997-05-08       Impact factor: 3.575

2.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

3.  Characterization of structural domains of human osteoclastogenesis inhibitory factor.

Authors:  K Yamaguchi; M Kinosaki; M Goto; F Kobayashi; E Tsuda; T Morinaga; K Higashio
Journal:  J Biol Chem       Date:  1998-02-27       Impact factor: 5.157

Review 4.  Estrogen and bone metabolism.

Authors:  H K Väänänen; P L Härkönen
Journal:  Maturitas       Date:  1996-05       Impact factor: 4.342

Review 5.  Molecular control of bone remodeling and osteoporosis.

Authors:  Y Y Kong; J M Penninger
Journal:  Exp Gerontol       Date:  2000-10       Impact factor: 4.032

6.  [Expression of human osteoprotegerin gene in E. Coli and bioactivity analysis of expression product].

Authors:  Ji-zhong Liu; Yun-yu Hu; Zong-ling Ji; Su-min Chen
Journal:  Zhonghua Wai Ke Za Zhi       Date:  2003-09

Review 7.  Recombinant expression systems in the pharmaceutical industry.

Authors:  F R Schmidt
Journal:  Appl Microbiol Biotechnol       Date:  2004-07-24       Impact factor: 4.813

8.  Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat.

Authors:  M Yamamoto; T Murakami; M Nishikawa; E Tsuda; S Mochizuki; K Higashio; T Akatsu; K Motoyoshi; N Nagata
Journal:  Endocrinology       Date:  1998-09       Impact factor: 4.736

9.  Production of recombinant human osteoprotegrin from Trichoplusia ni cells and Bombyx mori larvae.

Authors:  Zhen Liu; Guan-Zhen Yang; Xiang-Fu Wu
Journal:  Protein Pept Lett       Date:  2004-08       Impact factor: 1.890

Review 10.  RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.

Authors:  Y Wittrant; S Théoleyre; C Chipoy; M Padrines; F Blanchard; D Heymann; F Rédini
Journal:  Biochim Biophys Acta       Date:  2004-09-20
View more
  1 in total

1.  In vivo bioassay of recombinant human growth hormone synthesized in B. mori pupae.

Authors:  Hanglian Lan; Zuoming Nie; Yue Liu; Zhengbing Lv; Yingshuo Liu; Yanping Quan; Jianqing Chen; Qingliang Zhen; Qin Chen; Dan Wang; Qing Sheng; Wei Yu; Jian Chen; Xiangfu Wu; Yaozhou Zhang
Journal:  J Biomed Biotechnol       Date:  2010-03-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.